Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
More about the company